Smith+Nephew (NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery.
Analyzing real-world data from over 22,000 patients in the Premier PINC AI™ Healthcare Database, the analysis reveals that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to the PrevenaTM -125 mmHg sNPWT device.
An estimated 313 million surgical procedures are performed worldwide each year, with the number continuing to rise.2 In the United States, surgical site infections (SSIs) occur in approximately 2% to 4% of patients undergoing inpatient procedures.2,3
In relation to PrevenaTM sNPWT (-125mmHg), use of PICO sNPWT (-80mmHg) resulted in the following key study findings:
Cardiovascular Surgery (5,000+ patients)
• 57.8% relative reduction in wound dehiscence risk (P<0.01)
• 9.1% relative reduction in LoS (6.33 days vs. 6.86 days) (P<0.0001)
• 10.34% relative reduction in admission-related costs and 13% lower expenditures within three months post-surgery (P<0.0001)
Orthopedic Surgery (17,000+ patients)
• 63.9% relative reduction in wound dehiscence incidence (p<0.05)
• 29.7% relative reduction in LoS (2.43 days vs. 3.10 days) (p<0.0001)
• 21.95% relative reduction in mean index admission cost and a 21% reduction at 30- and 90-day post-surgery (p<0.001)
SNN shares reached noon EDT Monday down 18 cents to $36.41.
